MOLECULAR EXPRESS, INC.

Biotech · Private

Synthetic lung surfactant (ME-1001) comprising Super Mini-B peptide and natural lipids for neonatal respiratory distress syndrome

Grants
$9.8M
20 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
12
2 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Design and Engineering of Nanoparticulate Universal Vaccines$290,263
Federal grantDepartment of Health and Human Services · Phase I · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$329,911
Federal grantDepartment of Health and Human Services · Phase I · Development of a Gene and Oligonucleotide Delivery System$322,946
Federal grantDepartment of Health and Human Services · Phase II · Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction$225,033
Federal grantDepartment of Health and Human Services · Phase I · Optimization of VesiVax® Lipidated Tucaresol Formulations$225,000
Federal grantDepartment of Health and Human Services · Phase II · The VesiVax® System: Vaccine Development Made Easy$762,253
Federal grantDepartment of Health and Human Services · Phase II · Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction$95,143
Federal grantDepartment of Health and Human Services · Phase I · VesiVax® Peanut Allergy Immunotherapy$300,000
Federal grantDepartment of Health and Human Services · Phase II · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$934,456
Federal grantDepartment of Health and Human Services · Phase II · The VesiVax® System: Vaccine Development Made Easy$736,747
Federal grantDepartment of Health and Human Services · Phase II · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$497,338
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$956,889
Federal grantDepartment of Health and Human Services · Phase I · VesiVax Vaccine Formulation Against Neisseria gonorrhoeae$299,817
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$1,031,789
Federal grantDepartment of Health and Human Services · Phase I · Niclosamide Formulations for the Treatment of Influenza Infections$298,479
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$67,200
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$113,400
Federal grantDepartment of Health and Human Services · Phase I · VesiVax Vaccine Formulation Against Neisseria gonorrhoeae$299,779
Federal grantDepartment of Health and Human Services · Phase II · Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,853
Federal grantDepartment of Health and Human Services · Phase II · Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,784
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1925Arch Innotek, LLC——
1926GENELANCET BIOSCIENCES INC——
1927CODA Biotherapeutics, Inc.——
1928MOLECULAR EXPRESS, INC.——
1929Surf Air Global Ltd—$9.9M
1930GENOMEDESIGNS LABORATORY, LLC——
1931Prologue Medicines——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 12
  • Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofgranted
  • Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofapplication
  • Methods And Compositions For Liposomal Formulation Of Antigens And Uses Thereofgranted
  • Foam Patent Surfactantapplication
  • Foam Patent Surfactantapplication
  • Light Activated Nanoparticle Compositions And Uses Thereofapplication
  • Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofapplication
  • Nanoparticle Formulations Of Poorly Soluble Compoundsapplication
  • Surfactant Preparations For Pulmonary Delivery, And Methods For The Preparation And Use Thereofapplication
  • Liposomal Formulationsapplication
  • Surfactant Preparations For Pulmonary Delivery, And Methods For The Preparation And Use Thereofapplication
  • Light Activated Nanoparticle Compositions And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.